Aerie Pharmaceuticals, Inc (AERI) is a leading drug manufacturers-specialty & generic business based in the US. Aerie Pharmaceuticals is listed on the NASDAQ and employs 380 staff. All prices are listed in US Dollars.
|52-week range||$9.01 - $22.7467|
|50-day moving average||$13.7528|
|200-day moving average||$12.3154|
|Wall St. target price||$26.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.169|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Revenue TTM||$83.1 million|
|Gross profit TTM||$42.3 million|
|Return on assets TTM||-25.13%|
|Return on equity TTM||-142.61%|
|Market capitalisation||$787 million|
TTM: trailing 12 months
There are currently 5.9 million Aerie Pharmaceuticals shares held short by investors – that's known as Aerie Pharmaceuticals's "short interest". This figure is 3.8% up from 5.6 million last month.
There are a few different ways that this level of interest in shorting Aerie Pharmaceuticals shares can be evaluated.
Aerie Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aerie Pharmaceuticals shares currently shorted divided by the average quantity of Aerie Pharmaceuticals shares traded daily (recently around 494023.03797468). Aerie Pharmaceuticals's SIR currently stands at 11.85. In other words for every 100,000 Aerie Pharmaceuticals shares traded daily on the market, roughly 11850 shares are currently held short.
However Aerie Pharmaceuticals's short interest can also be evaluated against the total number of Aerie Pharmaceuticals shares, or, against the total number of tradable Aerie Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aerie Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Aerie Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.1721% of the tradable shares (for every 100,000 tradable Aerie Pharmaceuticals shares, roughly 172 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Aerie Pharmaceuticals.
Find out more about how you can short Aerie Pharmaceuticals stock.
We're not expecting Aerie Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Aerie Pharmaceuticals's shares have ranged in value from as little as $9.01 up to $22.7467. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerie Pharmaceuticals's is 0.7889. This would suggest that Aerie Pharmaceuticals's shares are less volatile than average (for this exchange).
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.